CDK7-IN-33
CDK7-IN-33 is an orally active pyrimidine derivative and also a CDK7 kinase inhibitor. CDK7-IN-33 is applicable to the research of cancer, inflammation, cardiovascular diseases, infectious diseases, immune diseases and metabolic diseases.
For research use only. We do not sell to patients.
- CAS No.: 2640208-32-6
- Formula: C21H20F6N6O2
- Molecular Weight:502.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
CDK7 |
In Vitro
CDK7-IN-33 (formula I) maleate crystal form Form I (0.15-333.33 nM; 3 days) potently inhibits the proliferation of 23 human cancer cell lines including ovarian, colorectal, breast, lung, pancreatic, leukemia, and lymphoma cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax | T1/2 | AUClast |
|---|---|---|---|---|---|---|
| Rat[1] | 10 mg/kg | i.g. | 4 h | 502 ng/mL | 2.99 h | 4260 ng·h/mL |
Chemical Information
-
CAS No. 2640208-32-6
-
Molecular Weight 502.41
-
Formula C21H20F6N6O2
-
SMILES
COC(NC1=CC=C2C(C3=C(C=NC(N[C@H]4CCCNC4)=N3)C(F)(F)F)=CNC2=C1C(F)(F)F)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)